LETTER TO THE EDITOR

# In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myeloma

Sina Wenger,[1,2] Milena Pantic,[1,2] Gabriele Ihorst,[2,3] Stepan Cysar,[4] Marc-Antoine Calba,[4] Christine Greil,[1,2] Ralph Wäsch[1,2] and Monika Engelhardt[1,2]

[1]Department of Medicine I Hematology and Oncology, Faculty of Medicine and Medical Center, University of Freiburg (UKF); [2]Tumor Center Freiburg, Comprehensive Cancer Center Freiburg (CCCF); [3]Clinical Trials Unit, Faculty of Medicine, University of Freiburg and [4]Department of Pathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Correspondence:
M. ENGELHARDT - monika.engelhardt@uniklinik-freiburg.de

https://doi.org/10.3324/haematol.2023.283142

Received: March 17, 2023.
Accepted: August 9, 2023.
Early view: August 17, 2023.

# Supplements

## Suppl. Table 1. Subgroup 2 (no IgH-translocation/hyperdiploidy, but other cytogenetic aberrations; n=40) divided based on their monosomy 13/del13q14-status

| **Subgroup 2** (n=40) | **(a) patients with only Monosomy 13 / del13q14** (n=3) | **(b) patients with Monosomy 13 / del13q14 and ≥1 additional cytogenetic event** (n=34) | **(c) patients without Monosomy 13 / del13q14** (n=3) |
|---|---|---|---|
| **Demographic data** | | | |
| Age at ID *[years; median / mean (range)]* | 57 (56 - 60) | 62 (46 - 89) | 73 (70 - 73) |
| Gender: male / female *[n (%)]* | 3 (100) / 0 | 18 (53) / 16 (47) | 1 (33) / 2 (67) |
| KPS *[%; median (range)]* | 90 (90 - 100) | 80 (20 - 100) | 90 (70 - 100) |
| **Type of MM** *[n (%)]* | | | |
| IgG / IgA / LC | 1 (33) / 0 / 2 (67) | 13 (38) / 9 (27) / 12 (35) | 3 (100) / 0 / 0 |
| κ : λ LC type | 2 (67) / 1 (33) | 18 (53) / 16 (47) | 1 (33) / 2 (67) |
| **Risk stratification** *[n (%)]* | | | |
| ISS I / II / III | 1 (33) / 0 / 2 (67) | 9 (27) / 13 (38) / 12 (35) | 0 / 2 (67) / 1 (33) |
| R-ISS I / II / III | 0 / 2 (67) / 1 (33) | 4 (12) / 22 (64) / 8 (24) | 0 / 2 (67) / 1 (33) |
| R-MCI<br>fit (0-3) / intermediate-fit (4-6)<br>frail (7-9) | <br>2 (67) / 1 (33)<br>0 | <br>9 (26) / 16 (48)<br>9 (26) | <br>0 / 2 (67)<br>1 (33) |
| **Outcome** *[n (%)]* | | | |
| Pts alive *(yes / no)* | 3 (100) / 0 | 23 (68) / 11 (32) | 2 (67) / 1 (33) |
| PFS [*month; median (range)]* | 43 (32 - 49) | 41 (0 - 288) | 13 (9 - 57) |
| **p-value of (a), (b) and (c)* | *0.5549* | | |
| OS [*month; median (range)]* | not reached (92 - 128) | 116 (0 - 288) | 21 (13 - 62) |
| **p-value of (a), (b) and (c)* | *0.1134* | | |

**Abbreviations**: ID=initial diagnosis, KPS=Karnofsky-Performance-Status, LC=light chain, ISS=International Staging System, R-ISS=Revised-International Staging System, R-MCI=Revised-Myeloma Comorbidity Score, pts=patients, PFS=Progression Free Survival, OS=Overall Survival.

*****Kaplan-Meier analysis revealed p-values of *0.5549* for PFS and *0.1134* for OS when comparing patients with exclusively monosomy 13/del13q14 (a) vs. those with monosomy 13/del13q14 accompanied by secondary aberrations (b) vs. patients without monosomy 13/del13q14 but various other cytogenetic aberrations (c); the non-significance likely related to limited numbers of patients.

## Suppl. Table 2. Technical specifications for IHC antibodies

| **Target** | **Vendor** | **Clone** | **Dilution** | **Species** | **Staining** |
|---|---|---|---|---|---|
| Cyclin D1 | Dako/Aligent | EP12 | ready to use | rabbit | nucleus |
| Cyclin D2 | Abcam | ab230883 | 1:10.000 | rabbit | nucleus |
| Cyclin D3 | CellSignaling | DCS-22 | 1:500 | mouse | cytoplasm |